Systemic lupus erythematosus and lupus nephritis Musculoskeletal Diseases Systemic lupus erythematosus
Conditions
Interventions
Prednisone/Prednisilone 7.5 mg versus placebo
Sponsors
University of Calgary (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18 years of age or older 2. American College of Rheumatology defined systemic lupus erythematosus 3. International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis on last renal biopsy 4. In complete or partial remission 5. Currently on corticosteroids 6. Informed consent
Exclusion criteria
Exclusion criteria: 1. Receiving steroids for a non-Systemic Lupus Erythematosus (SLE) indication 2. Currently pregnant 3. On a form of renal replacement therapy or having received a renal transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to flare of SLE | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Time to renal flare 2. Differences in quality of life as measured by Short Form - 36 and Euroquol 5D instrument 3. Differences in disease activity as measured by British Isles Lupus Activity Grade and Systemic Lupus Erythematosus Activity Index 4. Differences in disease damage as measured by the Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) damage score 5. Differences in steroid-related adverse events | — |
Countries
Canada, United Kingdom
Outcome results
None listed